NCT00304629View on ClinicalTrials.gov

Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

241

Participants

Timeline

Start Date

March 31, 2000

Study Completion Date

March 31, 2002

Conditions
Alzheimer Disease
Interventions
DRUG

galantamine

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00304629 - Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease | Biotech Hunter | Biotech Hunter